APLS Q4 2024 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$213M+45.2% YoY

Gross Profit

$172M80.8% margin

Operating Income

-$26M-12.3% margin

Net Income

-$36M-17.1% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+8.0%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$19M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$885M

Total Liabilities

$657M

Stockholders' Equity

$229M

Cash & Equivalents

$411M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$213M	$146M	+45.2%
Gross Profit	$172M	$126M	+35.7%
Operating Income	-$26M	-$85M	+69.0%
Net Income	-$36M	-$89M	+59.0%

Revenue Segments

Product

$191M90%

Licensing And Other Revenue

$21M10%